Moderna ( (MRNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moderna’s share price climbed after the company reported encouraging five‑year Phase 2 data for its experimental cancer vaccine, drawing investor attention back to its broader drug pipeline. The move comes even as the stock remains volatile due to falling COVID vaccine sales and recent cash losses. In response, analysts have been adjusting their price targets, trying to balance the long‑term growth potential from Moderna’s oncology, rare‑disease and new vaccine programs against near‑term revenue pressure, regulatory and market‑access challenges, and ongoing insider and legal overhangs. Upcoming readouts from Phase 1–3 trials and long‑term extension studies are seen as key future catalysts, but operational and scaling risks continue to temper market optimism.
More about Moderna
YTD Price Performance: 68.90%
Average Trading Volume: 11,650,136
Technical Sentiment Signal: Buy
Current Market Cap: $16.8B
For further insights into MRNA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.